MiMedx Group Company Profile (NASDAQ:MDXG)

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

MiMedx Group announced that its Board of Directors has approved a share buyback plan on Monday, April 10th 2017, which allows the company to repurchase $10,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's management believes its shares are undervalued.

MiMedx Group, Inc (NASDAQ:MDXG) announced its quarterly earnings results on Friday, April, 28th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.00. The business had revenue of $72.60 million for the quarter, compared to analysts' expectations of $72.60 million. MiMedx Group had a net margin of 5.72% and a return on equity of 12.25%. The firm's revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.04 EPS. View MiMedx Group's Earnings History.

MiMedx Group updated its FY17 earnings guidance on Friday, April, 28th. The company provided earnings per share guidance of $0.31-0.33 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.32. The company issued revenue guidance of $303.5-307.0 million, compared to the consensus revenue estimate of $304.53 million.

4 equities research analysts have issued 12 month price targets for MiMedx Group's stock. Their predictions range from $10.00 to $20.00. On average, they expect MiMedx Group's share price to reach $13.25 in the next year. View Analyst Ratings for MiMedx Group.

Here are some recent quotes from research analysts about MiMedx Group stock:

• 1. Needham & Company LLC analysts commented, "We expect the upcoming top line data from MDXG’s diabetic foot ulcer (DFU) and venous leg ulcer (VLU) multi-center randomized controlled trials (RCTs) to be positive catalysts. MDXG disclosed positive interim results from the VLU RCT during its 3/9/17 investor call. Assuming good final results, we expect the trials to drive growth by prompting more insurers to cover EpiFix and more physicians to use EpiFix." (6/26/2017)
• 2. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (2/21/2017)

MiMedx Group saw a decrease in short interest in June. As of June 30th, there was short interest totalling 20,263,818 shares, a decrease of 10.9% from the June 15th total of 22,752,219 shares. Based on an average daily trading volume, of 1,353,029 shares, the days-to-cover ratio is currently 15.0 days. Approximately 19.8% of the shares of the company are short sold.

Some companies that are related to MiMedx Group include LivaNova PLC (LIVN), Nevro Corp. (NVRO), Neogen Corporation (NEOG), Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), CONMED Corporation (CNMD), Asante Solutions (PUMP), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), Intersect ENT (XENT), AtriCure (ATRC), CryoLife (CRY), Meridian Bioscience (VIVO), Landauer (LDR) and Invacare Corporation (IVC).

MiMedx Group's management team includes the folowing people:

• Parker H. Petit Jr., Chairman of the Board, Chief Executive Officer
• William Charles Taylor, President, Chief Operating Officer, Director
• Michael J. Senken, Chief Financial Officer
• Alexandra O. Haden, General Counsel, Secretary
• Charles E. Koob, Director
• Luis A. Aguilar, Independent Director
• Joseph G. Bleser, Independent Director
• J. Terry Dewberry, Independent Director
• Charles R. Evans, Independent Director

MiMedx Group's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.33%), Summit Creek Advisors LLC (0.33%), Westwood Management Corp IL (0.23%), Acadian Asset Management LLC (0.12%), Strs Ohio (0.06%) and Boston Advisors LLC (0.05%). Company insiders that own MiMedx Group stock include Alexandra O Haden, Charles Robert Evans, Parker H Petit and William Charles Taylor. View Institutional Ownership Trends for MiMedx Group.

MiMedx Group's stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Boston Advisors LLC, Capstone Asset Management Co. and LS Investment Advisors LLC. View Insider Buying and Selling for MiMedx Group.

MiMedx Group's stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Strs Ohio, Russell Investments Group Ltd., State of Alaska Department of Revenue, Aperio Group LLC and Louisiana State Employees Retirement System. Company insiders that have bought MiMedx Group stock in the last two years include Alexandra O Haden, Charles Robert Evans and Parker H Petit. View Insider Buying and Selling for MiMedx Group.

Shares of MiMedx Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MiMedx Group stock can currently be purchased for approximately $14.65.